David Sternberg
Overview
Explore the profile of David Sternberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
354
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harfouch O, Whitfield D, Mammadli T, Eyasu R, Volpi C, Mansfield M, et al.
AIDS Patient Care STDS
. 2025 Jan;
39(2):36-43.
PMID: 39866129
In a cohort of transgender women (TGW) with abnormal anal cytology (AAC) in Washington, DC, we determined the rates of and factors associated with completion of high-resolution anoscopy (HRA). This...
2.
Harfouch O, Lisco A, Omari H, Eyasu R, Davis A, Zoltick M, et al.
Open Forum Infect Dis
. 2024 Dec;
11(12):ofae662.
PMID: 39679352
Background: Transgender people assigned male at birth (TG-AMAB) have higher rates of anal human papillomavirus (HPV) infection and anal cancer compared with cisgender populations. In a cohort of TG-AMAB in...
3.
Capozzi E, Daniels J, Mohamed H, Mejia F, Sternberg D, Bouey J, et al.
Am J Reprod Immunol
. 2024 Sep;
92(3):e13929.
PMID: 39302204
Problem: Female sex workers (FSW) experience a disproportionately high burden of HIV infection, yet characterization of the vaginal immune microenvironment that may impact biological risk is not well studied among...
4.
Patel J, Meng J, Le H, Tanaka Y, Phani S, Salas M, et al.
Adv Ther
. 2024 Jul;
41(8):3299-3315.
PMID: 38958845
Introduction: For patients with epidermal growth factor receptor-mutated (EGFRm) locally advanced/metastatic non-small cell lung cancer (mNSCLC) whose disease has progressed on or after osimertinib and platinum-based chemotherapy (PBC), no uniformly...
5.
Hill K, Kattakuzhy S, Silk R, Eyasu R, Ogbumbadiugha O, Ebah E, et al.
Open Forum Infect Dis
. 2022 Oct;
9(10):ofac476.
PMID: 36225745
Background: Individuals with hepatitis C (HCV) represent a population that may benefit from pre-exposure prophylaxis (PrEP), given the overlapping risk factors and transmission networks of HCV and HIV. This analysis...
6.
Brokus C, Kattakuzhy S, Gayle B, Narayanan S, Davis A, Cover A, et al.
Open Forum Infect Dis
. 2022 Feb;
9(3):ofab658.
PMID: 35187191
Background: Daily oral preexposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) prevents human immunodeficiency (HIV) among people who inject drugs (PWID). Despite rising HIV incidence and injection drug use...
7.
Yeo E, Kralles H, Sternberg D, Mccullough D, Nadanasabesan A, Mayo R, et al.
Harm Reduct J
. 2021 Dec;
18(1):127.
PMID: 34886850
Background: The COVID-19 pandemic has had especially devastating effects on people who use drugs. Due to pandemic protocols in the USA, medication-assisted treatment (MAT) regulations became more flexible, permitting our...
8.
Janne P, Baik C, Su W, Johnson M, Hayashi H, Nishio M, et al.
Cancer Discov
. 2021 Sep;
12(1):74-89.
PMID: 34548309
Receptor tyrosine-protein kinase ERBB3 (HER3) is expressed in most -mutated lung cancers but is not a known mechanism of resistance to EGFR inhibitors. HER3-DXd is an antibody-drug conjugate consisting of...
9.
Hill K, Nussdorf L, Mount J, Silk R, Gross C, Sternberg D, et al.
J Addict Med
. 2021 Feb;
16(1):10-17.
PMID: 33560694
Objective: The ANCHOR program offered buprenorphine treatment to people who inject drugs engaged in hepatitis C (HCV) treatment at a Washington, DC harm reduction organization. This analysis describes the program...
10.
Rosenthal E, Silk R, Mathur P, Gross C, Eyasu R, Nussdorf L, et al.
Clin Infect Dis
. 2020 Feb;
71(7):1715-1722.
PMID: 32009165
Background: People who inject drugs have a high prevalence of hepatitis C virus (HCV) and significant disease associated with drug use; however, HCV treatment often occurs in absence of interventions...